Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin

Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin Stefan Glück Oncologist 2005; 10: 780-791 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the value of adjuvant chemotherapy in early breast cancer. Critically assess the use of anthracyclines as part of adjuvant chemotherapy. Describe the delivery of anthracyclines regarding dose, dose intensity, and dose density. Evaluate the use of trastuzumab in the adjuvant setting. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 28, 2005 Most Recent Review: Nov. 28, 2005* Most Recent Update: Nov. 28, 2005 Date Credit Expires: Nov. 28, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.